CMRX Chimerix Inc
Price (delayed)
$8.52
Market cap
$799.21M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.99
Enterprise value
$768.62M
Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious
Highlights
The debt has plunged by 65% YoY and by 29% from the previous quarter
The company's gross profit fell by 35% YoY but it rose by 33% QoQ
Chimerix's revenue has decreased by 35% YoY but it has increased by 33% from the previous quarter
CMRX's quick ratio is down by 44% year-on-year and by 10% since the previous quarter
The equity has declined by 37% year-on-year and by 10% since the previous quarter
Key stats
What are the main financial stats of CMRX
Market
Valuations
Earnings
Shares outstanding
93.8M
Market cap
$799.21M
Enterprise value
$768.62M
Price to earnings (P/E)
N/A
Price to book (P/B)
6.3
Price to sales (P/S)
3,604.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,625.56
Revenue
$212,000
Gross profit
$212,000
Operating income
-$96.57M
Net income
-$88.39M
EBIT
-$88.39M
EBITDA
-$88.41M
Free cash flow
-$75.26M
Per share
Balance sheet
Liquidity
EPS
-$0.99
EPS diluted
-$0.99
Free cash flow per share
-$0.84
Book value per share
$1.35
Revenue per share
$0
TBVPS
$1.63
Total assets
$146.01M
Total liabilities
$24.33M
Debt
$458,000
Equity
$121.68M
Working capital
$112.08M
Debt to equity
0
Current ratio
5.7
Quick ratio
5.52
Net debt/EBITDA
0.35
Margins
Efficiency
Dividend
EBITDA margin
-41,700.9%
Gross margin
100%
Net margin
-41,692%
Operating margin
-45,550.5%
Return on assets
-52.2%
Return on equity
-60.2%
Return on invested capital
-70.2%
Return on capital employed
-72.4%
Return on sales
-41,692%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CMRX stock price
How has the Chimerix stock price performed over time
Intraday
0.24%
1 week
0%
1 month
62.29%
1 year
743.56%
YTD
144.83%
QTD
0.12%
Financial performance
How have Chimerix's revenue and profit performed over time
Revenue
$212,000
Gross profit
$212,000
Operating income
-$96.57M
Net income
-$88.39M
Gross margin
100%
Net margin
-41,692%
The net margin has plunged by 65% YoY but it has grown by 21% from the previous quarter
The company's operating margin has shrunk by 59% YoY but it rose by 22% QoQ
The company's gross profit fell by 35% YoY but it rose by 33% QoQ
Chimerix's revenue has decreased by 35% YoY but it has increased by 33% from the previous quarter
Growth
What is Chimerix's growth rate over time
Valuation
What is Chimerix stock price valuation
P/E
N/A
P/B
6.3
P/S
3,604.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,625.56
The EPS has contracted by 6% YoY and by 4.2% from the previous quarter
The stock's price to book (P/B) is 117% more than its 5-year quarterly average of 2.9
The equity has declined by 37% year-on-year and by 10% since the previous quarter
CMRX's P/S is 197% higher than its last 4 quarters average of 1212.5
Chimerix's revenue has decreased by 35% YoY but it has increased by 33% from the previous quarter
Efficiency
How efficient is Chimerix business performance
Chimerix's ROIC has plunged by 71% YoY and by 22% from the previous quarter
The ROS has plunged by 65% YoY but it has grown by 21% from the previous quarter
Chimerix's return on equity has shrunk by 59% YoY and by 19% QoQ
CMRX's return on assets is down by 49% year-on-year and by 16% since the previous quarter
Dividends
What is CMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CMRX.
Financial health
How did Chimerix financials performed over time
The current ratio has declined by 44% year-on-year and by 10% since the previous quarter
CMRX's quick ratio is down by 44% year-on-year and by 10% since the previous quarter
The debt is 100% less than the equity
The debt to equity has shrunk by 100% YoY
The debt has plunged by 65% YoY and by 29% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.